Probody therapeutics for targeting antibodies to diseased tissue

Abstract C158: Tumor-specific inhibition of jagged-dependent notch signaling using a Probody  therapeutic.

(2014) J. Sagert et al.   MOLECULAR CANCER THERAPEUTICS

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics

(2013) Hans-Peter Gerber et al.   NATURAL PRODUCT REPORTS

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

Targeting the Notch Pathway: Twists and Turns on the Road to Rational Therapeutics

(2012) Jon C. Aster et al.   JOURNAL OF CLINICAL ONCOLOGY

Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging a functional tumorigenic biomarker in the transformed epithelium

(2012) A. M. LeBeau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)

(2012) Jennifer D. Stone et al.   OncoImmunology

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

(2011) N. Azzopardi et al.   CLINICAL CANCER RESEARCH